Dr. Bauer is Professor, Emeritus, at Stanford University School of Medicine.

Eugene Bauer, MD, will join the American Skin Association’s (ASA) Board of Directors. 

Dr. Bauer is Professor, Emeritus, at Stanford University School of Medicine. He is immediate past co-founder, Chief Medical Officer, and member of the Board of Directors of Dermira, Inc., a biotechnology company recently acquired by Eli Lilly and Company.

"We are proud to announce the addition of Dr. Eugene Bauer to ASA's Board of Directors. Dr. Bauer's experience in both dermatology and the pharmaceutical industry will be a tremendous asset to our board," says Howard P. Milstein, Chairman of ASA, in a news release.

"Dr. Bauer is a wonderful addition to our Board of Directors! We look forward to working with him as we continue to work towards our vital mission and provide hope to those suffering from skin diseases," adds Dr. David Norris, President of ASA.

Before initiating a career in the pharmaceutical industry, Dr. Bauer served as Chairman of the Department of Dermatology (1988-1995) and as the Dean of the School of Medicine (1995-2001) of Stanford University. He was a National Institutes of Health (NIH)-funded investigator for 25 years and has served on numerous advisory groups for the NIH. He has been elected to several honorific societies, including the National Academy of Medicine of the United States.

Prior to founding Dermira, Dr. Bauer served as a member of the board of directors of Peplin, Inc., where he also was its President and Chief Medical Officer, until Peplin's acquisition by LEO Pharma in 2009. During 2004-2008, Dr. Bauer was Chief Executive Officer of Neosil, Inc., a clinical-stage dermatology company, acquired by Peplin, Inc., in 2008. Prior to that, he was co-founder and member of the Board of Directors at Connetics, a commercial dermatology company.